Chardan downgraded Seres Therapeutics (MCRB) to Neutral from Buy with a $6 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCRB:
- Seres Therapeutics Reports Positive Q1 2025 Results
- Seres Therapeutics’ Positive Earnings Call: Progress and Challenges
- Seres Therapeutics Advances SER-155 Program with FDA Submission
- Seres Therapeutics reports Q1 EPS $3.75, consensus $1.97
- MCRB Earnings Report this Week: Is It a Buy, Ahead of Earnings?